Torrent Pharmaceuticals has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Friday, May 22, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 9, 2026, and signed by Company Secretary Chintan M Trivedi.

Key Agenda Items for the Board Meeting

The Board meeting has been convened to address several significant matters. The following table outlines the key agenda items scheduled for deliberation:

Audited Financial Results for FY26

The primary agenda of the May 22, 2026 Board meeting is the consideration and approval of the audited financial results of the company for the year ended March 31, 2026. This is a mandatory disclosure requirement under applicable SEBI regulations, and the results, once approved, will be disseminated to the stock exchanges.

Dividend and Fund-Raising Plans

Alongside the financial results, the Board will consider the recommendation of a final dividend, if any, on the equity shares of the company for the year 2025-26. The Board will also take up enabling resolutions for raising funds through the following instruments:

• Issue of Equity Shares including Convertible Bonds/Debentures through Qualified Institutional Placement (QIP)
• Depository Receipts
• Any other permissible modes

If the Board approves the fund-raising resolution, the matter will subsequently be placed for shareholders' approval at the ensuing Annual General Meeting (AGM).

Regulatory Compliance

The intimation has been filed in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior notice to stock exchanges before Board meetings where financial results or dividend recommendations are to be considered. The notice was addressed to both BSE Limited and the National Stock Exchange of India Ltd.

Torrent Pharmaceuticals Limited successfully concluded an NCLT convened meeting of equity shareholders on April 28, 2026, where shareholders approved the proposed scheme of amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The meeting marks a significant milestone in the consolidation process between the two pharmaceutical companies.

Meeting Details and Proceedings

The NCLT convened meeting was conducted through video conferencing and other audio-visual means, commencing at 10:00 a.m. IST and concluding at 10:21 a.m. IST on April 28, 2026. Mahesh Gupta, appointed as Chairman for the NCLT convened meeting, presided over the proceedings with the requisite quorum being present.

Amalgamation Scheme Approval

The proposed scheme of amalgamation between J. B. Chemicals & Pharmaceuticals Limited (Transferor Company) and Torrent Pharmaceuticals Limited (Transferee Company) received approval from equity shareholders with the requisite majority. The approval was secured under the provisions of Section 230(6) of the Companies Act, 2013, which requires majority of equity shareholders and three-fourths in value of equity shareholders who cast their votes.

The voting process was conducted through both remote e-voting and e-voting at the meeting, ensuring compliance with the Companies Act, listing regulations, and circulars issued by the Ministry of Corporate Affairs. This dual voting mechanism provided shareholders with flexible participation options while maintaining regulatory compliance.

Regulatory Compliance and Next Steps

Torrent Pharmaceuticals has committed to disclosing the detailed results of remote e-voting and e-voting at the meeting along with the scrutinizer's report to stock exchanges separately. This disclosure will be made as required under Regulation 44(3) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company communicated the meeting proceedings to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the listing regulations. The successful approval of the amalgamation scheme represents a crucial step forward in the merger process between the two pharmaceutical entities.

Corporate Information

Torrent Pharmaceuticals Limited, incorporated with CIN L24230GJ1972PLC002126, operates from its registered office at Avirat, Thaltej Shilaj Road, Ahmedabad. The company maintains active communication channels for investor services and continues to ensure transparent disclosure of material developments to stakeholders and regulatory authorities.